<DOC>
	<DOCNO>NCT00001378</DOCNO>
	<brief_summary>This pilot , chemoprevention study . Patients receive fenretinide daily 25 every 28 day 4 month tamoxifen daily 23 month , begin second month fenretinide . Patients remove study unacceptable toxicity , development invasive breast cancer , dysfunctional uterine bleeding .</brief_summary>
	<brief_title>A Pilot Trial Tamoxifen 4-HPR ( 4-N-Hydroxyphenyl Retinamide ) Persons High Risk Developing Breast Cancer</brief_title>
	<detailed_description>This pilot chemo-prevention study combination tamoxifen 4-HPR person increase risk develop invasive breast cancer . The objective study determine acute cumulative toxicity tamoxifen 4-HPR high risk person ; assess feasibility obtain adequate tissue study potential intermediate biomarkers proliferative disease malignancy use nipple aspiration , four quadrant fine needle aspirate , breast core needle biopsy ; study effect tamoxifen 4-HPR TGF-beta isoforms proliferative marker ki67 PCNA pre- post-therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<mesh_term>Retinamide</mesh_term>
	<criteria>POPULATION CHARACTERISTICS : Women men increase risk development breast cancer least one follow criterion : Histologically document ductal carcinoma situ ( DCIS ) , include DCIS minimal invasion microinvasion . Histologically document lobular neoplasia , include lobular hyperplasia lobular carcinoma situ ( LCIS ) . Histologically documented atypical ductal hyperplasia postmenopausal woman . Histologically documented atypical ductal hyperplasia premenopausal woman 1 firstdegree relative ( mother sister ) diagnose breast cancer . Histologically documented atypical ductal hyperplasia premenopausal woman 3 relative diagnose breast cancer provide least 1 seconddegree relative . 3 first seconddegree relative diagnose breast ovarian cancer least 1 diagnosed breast cancer . 2 premenopausal ( age 50 ) firstdegree relative diagnose breast cancer . 1 firstdegree relative diagnose breast cancer least 1 relative extend pedigree ovarian cancer . 3 relative breast cancer least 1 firstdegree relative diagnose premenopausal breast cancer . Previously diagnose Stage I breast cancer surgery and/or radiotherapy ( without prior adjuvant chemo hormonal therapy ) . Positive BRCA1/BRCA2 gene . No history invasive breast cancer . No evidence malignancy breast gynecologic exam . Participants family history breast cancer see consultation Family Studies Branch , NCI . PRIOR/CONCURRENT THERAPY : Mastectomy lumpectomy plus radiotherapy require prior entry patient DCIS . Patients DCIS participate protocol NCIMB348 eligible . No participation breast cancer prevention study involve pharmacologic intervention . No prior chemotherapy hormonal therapy invasive breast cancer . At least 3 month since estrogen progesterone replacement therapy hormonal contraceptive . PATIENT CHARACTERISTICS : Age : 35 . Performance status : Ambulatory . Life expectancy : At least 10 year . Hematopoietic : Complete blood count normal . Hepatic : Bilirubin normal . Alkaline phosphate normal . AST normal . PT , PTT normal . No history bleed disorder . No history chronic hepatitis cirrhosis . Renal : Creatinine le 1.5 mg/dL . Cardiovascular : No history deep venous thrombosis . No history pulmonary embolus . Other : No allergy study medication . Capable tolerate multiple diagnostic procedure . No history abnormal vaginal bleeding . Hysterectomy vaginal bleeding benign etiology allow . No history retinal disease , macular degeneration , night blindness . No medical psychiatric risk due nonmalignant systemic disease would preclude study participation . No history malignancy except : Curatively treat nonmelanomatous skin cancer . Curatively treated situ cervical carcinoma . Hodgkin 's disease treat 5 year ago . No pregnant woman . Adequate contraception require fertile patient 12 month fenretinide 2 month tamoxifen .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 1999</verification_date>
	<keyword>4-Quadrant Fine Needle Aspiration</keyword>
	<keyword>Biomarkers</keyword>
	<keyword>Chemoprevention</keyword>
	<keyword>Nipple Suction Aspirates</keyword>
	<keyword>TGF Beta</keyword>
</DOC>